{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:00:32Z","timestamp":1790100032592,"version":"4.0.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the comparative effectiveness and safety of biosimilar antivascular endothelial growth factor (VEGF) versus reference anti-VEGF intravitreal injections for the treatment of retinal diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was performed on studies identified through searches of Ovid MEDLINE, Embase, and the Cochrane Library between January 2015 and September 2024. Studies evaluating effectiveness and\/or safety outcomes of biosimilar anti-VEGF were included. Meta-analysis was performed with a random-effects model. Risk of bias assessment was performed with the Joanna Briggs Institute tools, and certainty of evidence was evaluated with the Grading of Recommendations, Assessment, Development, and Evaluation criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 25 studies were included in the meta-analysis. Diagnoses studied were neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and polypoidal choroidal vasculopathy. There were no significant differences in final visual acuity, change in visual acuity, final retinal thickness, change in retinal thickness, and incidence of adverse events over a follow-up duration of 12 to 63.6 weeks. Subgroup analyses of randomized controlled trials, observational studies, age-related macular degeneration, diabetic macular edema, and agent-specific analysis (aflibercept and ranibizumab) were not significant. Findings are supported by evidence of moderate to high certainty as per the Grading of Recommendations, Assessment, Development, and Evaluation tool. There was a low to moderate risk of bias in the included study as per the Joanna Briggs Institute tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Biosimilar anti-VEGF is comparable with reference anti-VEGF regarding safety profile and visual outcomes. Future research should prioritize including diverse patient populations and adopting standardized, extended follow-up periods to enhance the assessment of long-term safety and effectiveness of biosimilars.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004807","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T21:00:09Z","timestamp":1771448409000},"page":"1682-1694","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["EFFECTIVENESS AND SAFETY OF BIOSIMILAR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL DISEASES"],"prefix":"10.1097","volume":"46","author":[{"given":"Bhadra U.","family":"Pandya","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-5376","authenticated-orcid":false,"given":"Ryan S.","family":"Huang","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaditeya","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshan","family":"Cao","sequence":"additional","affiliation":[{"name":"Research Design and Biostatistics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4644-3339","authenticated-orcid":false,"given":"Brian G.","family":"Ballios","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Ontario, Canada;"},{"name":"Donald K. Johnson Eye Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada;"},{"name":"Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-3086","authenticated-orcid":false,"given":"Tina","family":"Felfeli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Ontario, Canada;"},{"name":"The Institute of Health Policy, Management and Evaluation (IHPME), Dalla Lana School of Public Health, University of Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","first-page":"1010","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Basingstoke)"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40942-021-00343-3","article-title":"Future of anti-VEGF: biosimilars and biobetters","volume":"8","author":"Kapur","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R4-20260922","first-page":"1234","article-title":"A systematic review of U.S. biosimilar approvals: what evidence does the FDA require and how are manufacturers responding?","volume":"23","author":"Hung","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R5-20260922","first-page":"824","article-title":"Aflibercept biosimilars \u2013 update on the development progress","volume":"38","author":"Sharma","year":"2023","journal-title":"Eye (Basingstoke)"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/OPTH.S307746","article-title":"Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration","volume":"15","author":"Apsangikar","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"Bressler","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.oret.2023.05.005","article-title":"Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration","volume":"7","author":"Loewenstein","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"key":"R11-20260922","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1475-1313.2010.00766.x","article-title":"Transforming scales of measurement of visual acuity at the group level","volume":"30","author":"Khoshnood","year":"2010","journal-title":"Ophthalmic Physiol Opt"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4103\/ijo.IJO_2977_20","article-title":"Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: real-world evidence","volume":"69","author":"Kelkar","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40123-019-00228-7","article-title":"A multicenter, retrospective study (RE-ENACT 2) on the use of RazumabTM (world's first biosimilar ranibizumab) in wet age-related macular degeneration","volume":"9","author":"Sharma","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40123-020-00277-3","article-title":"A multicenter, retrospective study (RE-ENACT 2) on RazumabTM (world's first biosimilar ranibizumab) in retinal vein occlusion","volume":"9","author":"Sharma","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the world's first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"key":"R19-20260922","first-page":"1106","article-title":"Ranibizumab biosimilar (Razumab) vs innovator ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye (Basingstoke)"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40942-021-00293-w","article-title":"Safety and efficacy of RazumabTM (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study","volume":"7","author":"Sharma","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","article-title":"A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis \u00ae in patients with neovascular age-related macular degeneration","volume":"70","author":"Singh","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"e0275611","DOI":"10.1371\/journal.pone.0275611","article-title":"Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"17","author":"Yoon","year":"2022","journal-title":"PLoS One"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijo.IJO_2516_20","article-title":"Clinical efficacy and safety of razumab\u00ae (CESAR) study: our experience with the world's first biosimilar ranibizumab","volume":"69","author":"Verma","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40123-021-00416-4","article-title":"Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation","volume":"11","author":"Ratra","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40123-022-00507-w","article-title":"Innovator versus biosimilar ranibizumab in polypoidal choroidal vasculopathy: real-world evidence","volume":"11","author":"Soman","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R26-20260922","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/OPTH.S407219","article-title":"Biosimilar versus innovator molecule of ranibizumab in neovascular age-related macular degeneration (The BALANCE trial): real-world evidence","volume":"17","author":"Chakraborty","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R27-20260922","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40123-022-00463-5","article-title":"Comparison of innovator vs. biosimilar ranibizumab in treating diabetic macular edema: a multicenter retrospective study","volume":"11","author":"Chakraborty","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R28-20260922","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R29-20260922","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/02713683.2024.2323506","article-title":"Visual outcome and fluid changes between eyes with polypoidal choroidal vasculopathy receiving biosimilar CKD-701 or reference ranibizumab therapy: a post hoc analysis of a phase 3 randomized clinical trial","volume":"49","author":"Nam","year":"2024","journal-title":"Curr Eye Res"},{"key":"R30-20260922","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40123-024-00883-5","article-title":"Efficacy, safety and immunogenicity of Sun's ranibizumab biosimilar in neovascular age-related macular degeneration: a phase 3, double-blind comparative study","volume":"13","author":"Ghosh","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R31-20260922","doi-asserted-by":"crossref","first-page":"14752","DOI":"10.1038\/s41598-024-65815-6","article-title":"Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration","volume":"14","author":"Kang","year":"2024","journal-title":"Sci Rep"},{"key":"R32-20260922","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.oret.2024.02.012","article-title":"Evaluating the efficacy and safety of aflibercept biosimilar (P041) compared with originator product in patients with neovascular age-related macular degeneration","volume":"8","author":"Karkhaneh","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R33-20260922","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40123-023-00836-4","article-title":"Efficacy and safety of biosimilar QL1207 vs. the reference aflibercept for patients with neovascular age-related macular degeneration: a randomized phase 3 trial","volume":"13","author":"Li","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R34-20260922","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","article-title":"Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: the INSIGHT randomized clinical trial","volume":"142","author":"Bressler","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R35-20260922","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.oret.2024.06.013","article-title":"Biosimilar candidate CT-P42 in diabetic macular edema: 24-week results from a randomized, active-controlled, phase III study","volume":"8","author":"Wolf","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R36-20260922","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.3390\/jcm10143106","article-title":"Factors of anti-vascular endothelial growth factor therapy withdrawal in patients with neovascular age-related macular degeneration: implications for improving patient adherence","volume":"10","author":"Gomi","year":"2021","journal-title":"J Clin Med"},{"key":"R37-20260922","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"R38-20260922","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ceo.13706","article-title":"Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines","volume":"48","author":"Jackson","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R39-20260922","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","article-title":"Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan","volume":"12","author":"Yanagi","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R40-20260922","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2023.2247972","article-title":"The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries","volume":"23","author":"Calamia","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R41-20260922","doi-asserted-by":"crossref","first-page":"e001410","DOI":"10.1136\/bmjgh-2019-001410","article-title":"Insulin prices, availability and affordability in 13 low-income and middle-income countries","volume":"4","author":"Ewen","year":"2019","journal-title":"BMJ Glob Health"},{"key":"R42-20260922","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","article-title":"The role of generic medicines and biosimilars in oncology in low-income countries","volume":"24","author":"Renner","year":"2013","journal-title":"Ann Oncol"},{"key":"R43-20260922","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ophtha.2023.04.019","article-title":"The biosimilar paradox: how anti-vascular endothelial growth factor biosimilars could increase patient and overall health care costs","volume":"130","author":"Zhang","year":"2023","journal-title":"Ophthalmology"},{"key":"R44-20260922","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R45-20260922","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"74","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:17Z","timestamp":1790096417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004807"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004807","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}